Checkpoint Inhibitors Vault Into Frontline Settings Across Tumor Types

Rachel Narozniak
Published: Tuesday, Aug 06, 2019
By the end of 2018, the 57 oncology drugs launched from 2014 to 2018 had gained 89 indications across 23 cancer types. These new agents included numerous checkpoint inhibitors, which saw tremendous uptake based on their ability to dramatically improve patient outcomes.

Although CDK4/6 inhibitors were approved earlier in the United States, the European Union 5 (EU5)— France, Germany, Italy, Spain, and the United Kingdom—have reached similar rates of use, with 14.5 patients per 100,000 in the EU5 and 14.2 in the United States. In 2018, the number of patients treated with these drugs nearly tripled in the top 5 European countries compared with the number in 2017, increasing by just 7% in the United States in 2018, where these agents were well established 2 years earlier.
Global oncology trends 2019. IQVIA Institute for Human Data Science website. Published May 2019. Accessed July 16, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication